JP2001506983A - 新規な低密度リポ蛋白質結合性蛋白質並びにアテローム性動脈硬化症の診断及び治療におけるそれらの利用 - Google Patents
新規な低密度リポ蛋白質結合性蛋白質並びにアテローム性動脈硬化症の診断及び治療におけるそれらの利用Info
- Publication number
- JP2001506983A JP2001506983A JP52487098A JP52487098A JP2001506983A JP 2001506983 A JP2001506983 A JP 2001506983A JP 52487098 A JP52487098 A JP 52487098A JP 52487098 A JP52487098 A JP 52487098A JP 2001506983 A JP2001506983 A JP 2001506983A
- Authority
- JP
- Japan
- Prior art keywords
- lbp
- seq
- polypeptide
- amino acid
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010007622 LDL Lipoproteins Proteins 0.000 title claims abstract description 223
- 102000007330 LDL Lipoproteins Human genes 0.000 title claims abstract description 223
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 96
- 102000014914 Carrier Proteins Human genes 0.000 title claims abstract description 9
- 108091008324 binding proteins Proteins 0.000 title claims abstract description 9
- 238000011282 treatment Methods 0.000 title claims description 36
- 238000003745 diagnosis Methods 0.000 title description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 282
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 240
- 229920001184 polypeptide Polymers 0.000 claims abstract description 216
- 230000027455 binding Effects 0.000 claims abstract description 191
- 238000000034 method Methods 0.000 claims abstract description 179
- 239000003814 drug Substances 0.000 claims abstract description 143
- 229940079593 drug Drugs 0.000 claims abstract description 136
- 241001465754 Metazoa Species 0.000 claims abstract description 120
- 239000012634 fragment Substances 0.000 claims abstract description 105
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 100
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 100
- 239000002157 polynucleotide Substances 0.000 claims abstract description 100
- 230000004060 metabolic process Effects 0.000 claims abstract description 36
- 230000005856 abnormality Effects 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 101100280481 Caenorhabditis elegans lbp-2 gene Proteins 0.000 claims description 116
- 101100280477 Caenorhabditis elegans lbp-1 gene Proteins 0.000 claims description 108
- AKWUNZFZIXEOPV-UHFFFAOYSA-N 2-[4-[[3-[7-chloro-1-(oxan-4-ylmethyl)indol-3-yl]-1,2,4-oxadiazol-5-yl]methyl]piperazin-1-yl]acetamide Chemical compound C1CN(CC(=O)N)CCN1CC1=NC(C=2C3=CC=CC(Cl)=C3N(CC3CCOCC3)C=2)=NO1 AKWUNZFZIXEOPV-UHFFFAOYSA-N 0.000 claims description 103
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 100
- 101100446025 Caenorhabditis elegans lbp-3 gene Proteins 0.000 claims description 90
- 239000003795 chemical substances by application Substances 0.000 claims description 88
- 125000000539 amino acid group Chemical group 0.000 claims description 87
- 210000004027 cell Anatomy 0.000 claims description 87
- 102100035131 Lipopolysaccharide-binding protein Human genes 0.000 claims description 84
- 101710089435 Lipopolysaccharide-binding protein Proteins 0.000 claims description 84
- 150000007523 nucleic acids Chemical class 0.000 claims description 68
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 67
- 102000039446 nucleic acids Human genes 0.000 claims description 67
- 108020004707 nucleic acids Proteins 0.000 claims description 67
- 150000001413 amino acids Chemical group 0.000 claims description 50
- 239000002299 complementary DNA Substances 0.000 claims description 50
- 238000012360 testing method Methods 0.000 claims description 35
- 230000003902 lesion Effects 0.000 claims description 29
- 230000002378 acidificating effect Effects 0.000 claims description 28
- 230000000692 anti-sense effect Effects 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 22
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical class C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 19
- 230000002503 metabolic effect Effects 0.000 claims description 18
- 230000003143 atherosclerotic effect Effects 0.000 claims description 16
- 238000003384 imaging method Methods 0.000 claims description 15
- 238000001727 in vivo Methods 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 15
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 14
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 14
- 230000008859 change Effects 0.000 claims description 14
- 210000002744 extracellular matrix Anatomy 0.000 claims description 14
- 230000001105 regulatory effect Effects 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- 230000009261 transgenic effect Effects 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 210000004671 cell-free system Anatomy 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 230000001605 fetal effect Effects 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 230000004807 localization Effects 0.000 claims description 4
- 230000003278 mimic effect Effects 0.000 claims description 4
- 238000011002 quantification Methods 0.000 claims description 4
- FYYSIASRLDJUNP-WHFBIAKZSA-N Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FYYSIASRLDJUNP-WHFBIAKZSA-N 0.000 claims description 3
- 108010067787 Proteoglycans Proteins 0.000 claims description 3
- 102000016611 Proteoglycans Human genes 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 claims description 3
- 229920000140 heteropolymer Polymers 0.000 claims description 3
- 229920001519 homopolymer Polymers 0.000 claims description 3
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 3
- 230000002483 superagonistic effect Effects 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 2
- 229920000832 Cutin Polymers 0.000 claims 1
- 102000016942 Elastin Human genes 0.000 claims 1
- 108010014258 Elastin Proteins 0.000 claims 1
- 229920002549 elastin Polymers 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 230000009149 molecular binding Effects 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 81
- 235000001014 amino acid Nutrition 0.000 description 54
- 229940024606 amino acid Drugs 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 48
- 108020004414 DNA Proteins 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 27
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 24
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 description 24
- 238000003556 assay Methods 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 20
- 230000004048 modification Effects 0.000 description 20
- 238000012986 modification Methods 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- 239000000499 gel Substances 0.000 description 16
- 210000000709 aorta Anatomy 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 108010010234 HDL Lipoproteins Proteins 0.000 description 14
- 102000015779 HDL Lipoproteins Human genes 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000010561 standard procedure Methods 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 101150072740 Lbp gene Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 210000001367 artery Anatomy 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 206010003210 Arteriosclerosis Diseases 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 230000003511 endothelial effect Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 208000011775 arteriosclerosis disease Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000002703 mutagenesis Methods 0.000 description 8
- 231100000350 mutagenesis Toxicity 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 239000007993 MOPS buffer Substances 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 210000000702 aorta abdominal Anatomy 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- -1 for example Proteins 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000002427 irreversible effect Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 208000034189 Sclerosis Diseases 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 238000005266 casting Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000003038 endothelium Anatomy 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000009918 complex formation Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 3
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108010020346 Polyglutamic Acid Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000497 foam cell Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010073443 Ribi adjuvant Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 108010022164 acetyl-LDL Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000002299 affinity electrophoresis Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- WLNBMPZUVDTASE-HXIISURNSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO WLNBMPZUVDTASE-HXIISURNSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FMYBFLOWKQRBST-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]acetic acid;nickel Chemical compound [Ni].OC(=O)CN(CC(O)=O)CC(O)=O FMYBFLOWKQRBST-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241001214176 Capros Species 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 1
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 101000843477 Escherichia coli (strain K12) RNA-binding protein Hfq Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 1
- 241000701149 Human adenovirus 1 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241001626506 Philypnodon Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000543375 Sideroxylon Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical class [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000002742 combinatorial mutagenesis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000013156 embolectomy Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 125000001965 gamma-lactamyl group Chemical group 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000052249 human APOB Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 101150050780 nodal gene Proteins 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 230000000444 normolipidemic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003462 sulfoxides Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下記よりなる群から選択するメンバーを含む単離されたポリヌクレオチド: (a)SEQ ID NO:1に示したアミノ酸配列を含むポリペプチドをコードするポリ ヌクレオチド; (b)SEQ ID NO:2に示したアミノ酸配列を含むポリペプチドをコードするポリ ヌクレオチド; (c)SEQ ID NO:3に示したアミノ酸配列を含むポリペプチドをコードするポリ ヌクレオチド; (d)SEQ ID NO:4に示したアミノ酸配列を含むポリペプチドをコードするポリ ヌクレオチド; (e)SEQ ID NO:5に示したアミノ酸配列を含むポリペプチドをコードするポリ ヌクレオチド; (f)SEQ ID NO:6に示したアミノ酸配列を含むポリペプチドをコードするポリ ヌクレオチド; (g)SEQ ID NO:7に示したアミノ酸配列を含むポリペプチドをコードするポリ ヌクレオチド; (h)SEQ ID NO:8に示したアミノ酸配列を含むポリペプチドをコードするポリ ヌクレオチド; (i)SEQ ID NO:9に示したアミノ酸配列を含むポリペプチドをコードするポリ ヌクレオチド; (j)(a)〜(h)又は(i)のポリヌクレオチドとハイブリダイズすることができ 及び少なくとも約95%同一であるポリヌクレオチド(ここに、コードされるポ リペプチドは、LDLに結合することができる); (k)生物学的に活性なポリペプチド(a)〜(i)又は(j)の断片(ここに、コー ドされるポリペプチドは、LDLに結合することができる)。 2.前記のメンバーを下記よりなる群から選択する、請求項1に記載の単離され たポリヌクレオチド: (a)SEQ ID NO:7に示したアミノ酸配列のアミノ酸残基8〜22(SEQ ID NO :19)、8〜33(SEQ ID NO:20)、23〜33(SEQ ID NO:21)又は208〜 217(SEQ ID NO:22)を含むポリペプチドをコードするポリヌクレオチド; (b)SEQ ID NO:1及びSEQ ID NO:6に示したアミノ酸配列のアミノ酸残基14 〜43(SEQ ID NO:23)又は38〜43(SEQ ID NO:24)を含むポリペプチドを コードするポリヌクレオチド; (C)SEQ ID NO:2に示したアミノ酸配列のアミノ酸残基105〜120(SEQ I D NO:25)、105〜132(SEQ ID NO:26)、121〜132(SEQ ID NO:2 7)又は211〜220(SEQ ID NO:28)を含むポリペプチドをコードするポリ ヌクレオチド; (d)SEQ ID NO:5に示したアミノ酸配列のアミノ酸残基96〜110(SEQ ID NO:29)を含むポリペプチドをコードするポリヌクレオチド; (e)SEQ ID NO:8に示したアミノ酸配列のアミノ酸残基53〜59(SEQ ID NO :41)を含むポリペプチドをコードするポリヌクレオチド; (f)(a)〜(d)又は(e)のポリヌクレオチドとハイブリダイズすることができ 及び少なくとも約95%同一であるポリヌクレオチド(ここに、コードされるポ リペプチドは、LDLに結合することができる);及び (g)生物学的に活性なポリヌクレオチド(a)〜(e)又は(f)の断片(ここに、 コードされるポリペプチドは、LDLに結合することができる)。 3.前記のポリヌクレオチドがSEQ ID NO:10に示した核酸を含む、請求項1に 記載のポリヌクレオチド。 4.前記のポリヌクレオチドがSEQ ID NO:11に示した核酸を含む、請求項1に 記載のポリヌクレオチド。 5.前記のポリヌクレオチドがSEQ ID NO:12に示した核酸を含む、請求項1に 記載のポリヌクレオチド。 6.前記のポリヌクレオチドがSEQ ID NO:13に示した核酸を含む、請求項1に 記載のポリヌクレオチド。 7.前記のポリヌクレオチドがSEQ ID NO:14に示した核酸を含む、請求項1に 記載のポリヌクレオチド。 8.前記のポリヌクレオチドがSEQ ID NO:15に示した核酸を含む、請求項1に 記載のポリヌクレオチド。 9.前記のポリヌクレオチドがSEQ ID NO:16に示した核酸を含む、請求項1に 記載のポリヌクレオチド。 10.前記のポリヌクレオチドがSEQ ID NO:17に示した核酸を含む、請求項1 に記載のポリヌクレオチド。 11.前記のポリヌクレオチドがSEQ ID NO:18に示した核酸を含む、請求項1 に記載のポリヌクレオチド。 12.前記のポリヌクレオチドがSEQ ID NO:30に示した核酸を含む、請求項2 に記載のポリヌクレオチド。 13.前記のポリヌクレオチドがSEQ ID NO:31に示した核酸を含む、請求項2 に記載のポリヌクレオチド。 14.前記のポリヌクレオチドがSEQ ID NO:32に示した核酸を含む、請求項2 に記載のポリヌクレオチド。 15.前記のポリヌクレオチドがSEQ ID NO:33に示した核酸を含む、請求項2 に記載のポリヌクレオチド。 16.前記のポリヌクレオチドがSEQ ID NO:34に示した核酸を含む、請求項2 に記載のポリヌクレオチド。 17.前記のポリヌクレオチドがSEQ ID NO:35に示した核酸を含む、請求項2 に記載のポリヌクレオチド。 18.前記のポリヌクレオチドがSEQ ID NO:36に示した核酸を含む、請求項2 に記載のポリヌクレオチド。 19.前記のポリヌクレオチドがSEQ ID NO:37に示した核酸を含む、請求項2 に記載のポリヌクレオチド。 20.前記のポリヌクレオチドがSEQ ID NO:38に示した核酸を含む、請求項2 に記載のポリヌクレオチド。 21.前記のポリヌクレオチドがSEQ ID NO:39に示した核酸を含む、請求項2 に記載のポリヌクレオチド。 22.前記のポリヌクレオチドがSEQ ID NO:40に示した核酸を含む、請求項 2に記載のポリヌクレオチド。 23.前記のポリヌクレオチドがSEQ ID NO:42に示した核酸を含む、請求項2 に記載のポリペプチド。 24.前記のポリヌクレオチドをDNA及びRNAよりなる群から選択する、請 求項1に記載のポリヌクレオチド。 25.前記のポリヌクレオチドがゲノムDNAである、請求項1に記載のポリヌ クレオチド。 26.請求項1に記載の前記のポリヌクレオチドを含む組換えベクター。 27.請求項26に記載の前記の組換えベクターを含む細胞。 28.請求項27に記載の細胞をLDL結合性蛋白質を発現させる条件下で培養 することを含むLDL結合性蛋白質の製造方法。 29.下記よりなる群から選択するメンバーを含む単離されたポリペプチド: (a)SEQ ID NO:1に示したアミノ酸配列を有するポリペプチド; (b)SEQ ID NO:2に示したアミノ酸配列を有するポリペプチド; (c)SEQ ID NO:3に示したアミノ酸配列を有するポリペプチド; (d)SEQ ID NO:4に示したアミノ酸配列を有するポリペプチド; (e)SEQ ID NO:5に示したアミノ酸配列を有するポリペプチド; (f)SEQ ID NO:6に示したアミノ酸配列を有するポリペプチド; (g)SEQ ID NO:7に示したアミノ酸配列を有するポリペプチド; (h)SEQ ID NO:8に示したアミノ酸配列を有するポリペプチド; (i)SEQ ID NO:9に示したアミノ酸配列を有するポリペプチド; (j)(a)〜(h)又は(i)のポリペプチドと少なくとも約95%同一であるポリ ペプチド(ここに、該ポリペプチドは、LDLと結合することができる);及び (k)生物学的に活性なポリペプチド(a)〜(i)又は(j)の断片(ここに、該断 片は、LDLに結合することができる)。 30.前記のメンバーを下記よりなる群から選択する、請求項29に記載の単離 されたポリペプチド: (a)SEQ ID NO:7に示したアミノ酸配列のアミノ酸残基8〜22(SEQ ID NO: 19)、8〜33(SEQ ID NO:20)、23〜33(SEQ ID NO:21)又は208 〜217(SEQ ID NO:22)を有するポリペプチド; (b)SEQ ID NO:1及びSEQ ID NO:6に示したアミノ酸配列のアミノ酸残基14 〜43(SEQ ID NO:23)又は38〜43(SEQ ID NO:24)を有するポリペプチド ; (c)SEQ ID NO:2に示したアミノ酸配列のアミノ酸残基105〜120(SEQ I D NO:25)、105〜132(SEQ ID NO:26)、121〜132(SEQ ID NO:2 7)又は211〜220(SEQ ID NO:28)を有するポリペプチド; (d)SEQ ID NO:5に示したアミノ酸配列のアミノ酸残基96〜110(SEQ ID NO:29)を有するポリペプチド; (e)SEQ ID NO:8に示したアミノ酸配列のアミノ酸残基53〜59(SEQ ID NO :41)を有するポリペプチド; (f)(a)〜(d)又は(e)のポリペプチドと少なくとも約95%同一であるポリ ペプチド(ここに、該ポリペプチドは、LDLに結合することができる);及び (g)生物学的に活性なポリペプチド(a)〜(e)又は(f)の断片(ここに、該断 片は、LDLに結合することができる)。 31.動物がアテローム性動脈硬化症の危険にあるかどうかを測定する方法であ って、下記を含む当該方法: 一の動物を準備し;そして 該動物におけるLBP代謝又は構造の面を評価する(該LBP代謝又は構造の面 における異常は、アテローム性動脈硬化症の危険にあることの診断となる)。 32.前記のLBPをLBP−1、LBP−2及びLBP−3よりなる群から選 択する、請求項31に記載の方法。 33.前記のLBP代謝の面が該LBPのLDLに結合する能力である、請求項 31に記載の方法。 34.前記のLBP代謝の面が該LBPの動脈細胞外マトリクス構造成分に結合 する能力である、請求項31に記載の方法。 35.前記の成分を、プロテオグリカン、エラスチン、コラーゲン、フィブロネ クチン、ビトロネタチン及びインテグリンよりなる群から選択する、請求項34 に記載の方法。 36.前記の危険が正常動物に比較して減少した危険である、請求項31に記載 の方法。 37.前記の異常が不活性なLBPポリペプチドを生じる、請求項36に記載の 方法。 38.前記の危険が正常動物に比較して増大した危険である、請求項31に記載 の方法。 39.前記の異常がネイティブなLBPポリペプチドより一層高い活性を有する LBPポリペプチドを生じる、請求項38に記載の方法。 40.前記の動物が出生前の動物である、請求項31に記載の方法。 41.アテローム性動脈硬化症の治療に用いる薬剤を評価する方法であって、下 記を含む当該方法: 試験用の細胞、無細胞系又は動物を準備し; 薬剤を準備し; 該剤を該試験用細胞、無細胞系又は動物に治療上有効な量で投与し;そして該剤 のLBP代謝又は構造の面に対する効果を評価する(該LBP代謝又は構造の面 における変化は、該剤のアテローム性動脈硬化症の治療における有用性を示す) 。 42.前記の試験用細胞、無細胞系又は動物がLBP代謝の野生型パターンを有 する、請求項41に記載の方法。 43.前記の試験用細胞、無細胞系又は動物がLBP代謝の非野生型パターンを 有する、請求項41に記載の方法。 44.前記のLBPを、LBP−1、LBP−2及びLBP−3よりなる群から 選択する、請求項41に記載の方法。 45.前記の薬剤がLBP−1、LBP−2若しくはLBP−3ポリペプチド又 は生物学的に活性なこれらの断片若しくはアナログを含む、請求項41に記載の 方法。 46.前記の薬剤を、図1〜8及び9に示したアミノ酸配列(SEQ ID NO:1〜9) を含むポリペプチドよりなる群から選択する、請求項41に記載の方法。 47.前記の薬剤がLBP−1、LBP−2若しくはLBP−3ポリペプチド又 は生物学的に活性なこれらの断片若しくはアナログをコードする核酸を含む、請 求項41に記載の方法。 48.前記の薬剤を、図10〜17及び18に示したヌクレオチド配列(SEQ ID NO:10〜18)を含む核酸よりなる群から選択する、請求項41に記載の方法。 49.前記の薬剤がLBP調節配列をコードする核酸又は生物学的に活性なその 断片を含む、請求項41に記載の方法。 50.前記の薬剤を、前記のLBPポリペプチドに対する結合性分子及び前記の LBP核酸に対する結合性分子よりなる群から選択する、請求項41に記載の方 法。 51.前記の薬剤がアンチセンス核酸又はそのアナログである、請求項41に記 載の方法。 52.前記の薬剤を、前記のLBPの模倣物及び前記のLBPの結合性分子の模 倣物よりなる群から選択する、請求項41に記載の方法。 53.前記の薬剤が、LBPポリペプチドと免疫反応し得るポリクローナル若し くはモノクローナル抗体又はこれらの断片である、請求項41に記載の方法。 54.前記の薬剤を、LBPポリペプチドと免疫反応し得る天然の抗体、組換え 抗体、キメラ抗体及びヒト化抗体よりなる群から選択する、請求項41に記載の 方法。 55.前記の薬剤が、前記のLBPに対する天然のリガンドである、請求項41 に記載の方法。 56.前記の薬剤が、前記のLBPに対する人工のリガンドである、請求項41 に記載の方法。 57.前記の薬剤を、アンタゴニスト、アゴニスト及びスーパーアゴニストより なる群から選択する、請求項41に記載の方法。 58.前記の薬剤を、トランスジェニック細胞及びトランスジェニック動物より なる群から選択するメンバーに投与する、請求項41に記載の方法。 59.前記の薬剤を、前記の試験用細胞又は無細胞系にイン・ビトロで投与し、 もし前記のLBP代謝の面に前記の変化が起きれば、該剤を更に試験用動物に治 療上有効な量で投与し、該剤のLBP代謝の面に対する効果をイン・ビボで評価 する、請求項41に記載の方法。 60.請求項41において同定された薬剤。 61.LBPポリペプチドの結合性分子に対する結合を変化させる能力について 薬剤を評価する方法であって、下記を含む当該方法: 一の薬剤を準備し; LBPポリペプチドを準備し; 結合性分子を準備し; 該薬剤、該LBP及び該結合性分子を合わせ;そして 該LBPポリペプチドと該結合性分子とを含む複合体の形成を検出する(該薬 剤の不在時と比較しての該薬剤の存在下での該複合体の形成における変化は、該 薬剤が該LBPポリペプチドの該結合性分子への結合を変化させることを示す) 。 62.前記のLBPポリペプチドを、LBP−1、LBP−2及びLBP−3ポ リペプチドよりなる群から選択する、請求項61に記載の方法。 63.前記のLBPポリペプチドの前記の結合性分子への結合を変化させること が、その結合を阻害することである、請求項61に記載の方法。 64.前記のLBPポリペプチドの前記の結合性分子への結合を変化させること が、その結合を促進することである、請求項61に記載の方法。 65.前記の結合性分子を、ネイティブなLDL及び改変したLDLよりなる群 から選択する、請求項61に記載の方法。 66.前記の結合性分子が、動脈細胞外マトリクス構造成分である、請求項61 に記載の方法。 67.請求項61において同定された薬剤。 68.LBPポリペプチドに結合する能力について薬剤を評価する方法であって 、下記を含む当該方法: 一の薬剤を準備し; LBPポリペプチドを準備し; 該薬剤を該LBPポリペプチドと接触させ;そして 該薬剤の該LBPポリペプチドに結合する能力を評価する。 69.前記のLBPポリペプチドを、LBP−1、LBP−2及びLBP−3ポ リペプチドよりなる群から選択する、請求項68に記載の方法。 70.請求項68において同定された薬剤。 71.LBP調節配列をコードする核酸に結合する能力について薬剤を評価する 方法であって、下記を含む当該方法: 一の薬剤を準備し; LBP調節配列をコードする核酸を準備し; 該薬剤を該核酸と接触させ;そして 該薬剤の該核酸に結合する能力を評価する。 72.前記のLBP調節配列を、LBP−1、LBP−2及びLBP−3よりな る群から選択する、請求項71に記載の方法。 73.請求項71において同定された薬剤。 74.下記を含む、動物におけるアテローム性動脈硬化症の治療方法: アテローム性動脈硬化症の治療の必要な動物を準備し; LBP構造又は代謝の面を変えることのできる薬剤を準備し; 該薬剤を該動物に治療上有効な量で、該アテローム性動脈硬化症の治療を生じ るように投与する。 75.前記の薬剤がLBPポリペプチドである、請求項74に記載の方法。 76.前記のLBPポリペプチドがLBP−1、LBP−2若しくはLBP−3 ポリペプチド又は生物学的に活性なその断片又はアナログである、請求項75に 記載の方法。 77.前記の薬剤を、SEQ ID NO:1〜8及び9に示したアミノ酸配列を含むポリ ペプチドよりなる群から選択する、請求項76に記載の方法。 78.前記の薬剤を、SEQ ID NO:7に描いたヒトLBP−2のアミノ酸残基8〜 22(SEQ ID NO:19)、8〜33(SEQ ID NO:20)、23〜33(SEQ ID NO:2 1)又は208〜217(SEQ ID NO:22);SEQ ID NO:1及びSEQ ID NO:6に描 いたウサギ又はヒトのLBP−1のアミノ酸残基14〜43(SEQ ID NO:23)又 は38〜43(SEQ ID NO:24);SEQ ID NO:2に描いたアミノ酸残基105〜1 20(SEQ ID NO:25)、105〜132(SEQ ID NO:26)、121 〜132(SEQ ID NO:27)又は211〜220(SEQ ID NO:28);SEQ ID NO:5 に描いたウサギLBP−3のアミノ酸残基96〜110(SEQ ID NO:29);及 びSEQ ID NO:8に示したアミノ酸残基53〜59(SEQ ID NO:41)を含むポリペ プチドよりなる群から選択する、請求項76に記載の方法。 79.前記の薬剤が、約50アミノ酸残基長以下である、請求項74に記載の方 法。 80.前記の薬剤が、少なくとも約20%の酸性アミノ酸残基を含むアミノ酸配 列を有するポリペプチドである、請求項74に記載の方法。 81.前記の薬剤を、酸性アミノ酸のホモポリマー又はそのアナログ並びに一種 以上の酸性アミノ酸及び一種以上の他のアミノ酸のヘテロポリマー又はあそのア ナログよりなる群から選択する、請求項74に記載の方法。 82.前記の薬剤を、ポリ(glu)、ポリ(asp)及びポリ(glu asp)よ りなる群から選択する、請求項74に記載の方法。 83.前記の薬剤を、ポリ(glu N)、ポリ(asp N)及びポリ(glu asp N)よりなる群から選択する、請求項74に記載の方法。 84.前記の薬剤が、約10アミノ酸残基長以下のポリ(glu)である、請求項 74に記載の方法。 85.前記の薬剤が、LBP核酸又は生物学的に活性なその断片若しくはアナロ グである、請求項74に記載の方法。 86.前記のLBP核酸が、LBP−1、LBP−2若しくはLBP−3ポリペ プチド又は生物学的に活性なその断片又はアナログをコードする核酸を含む、請 求項85に記載の方法。 87.前記の薬剤を、SEQ ID NO:10〜17及び18に示したヌクレオチド配列 を含む核酸よりなる群から選択する、請求項86に記載の方法。 88.前記の薬剤がアンチセンス核酸又はそのアナログである、請求項74に記 載の方法。 89.下記を含む、アテローム性動脈硬化症の危険にある動物の治療方法: アテローム性動脈硬化症の危険にある動物を準備し; LBP構造又は代謝の面を変えることのできる薬剤を準備し;そして 該薬剤を該動物に治療上有効な量で、該動物の治療が生じるように投与する。 90.LBPの構造又は代謝に異常を有する細胞の治療方法であって、下記を含 む当該方法: LBPの構造又は代謝に異常を有する細胞を準備し; LBP構造又は代謝の面を変えることのできる薬剤を準備し;そして 該薬剤を該細胞に治療上有効な量で、該細胞の治療が生じるように投与する。 91.前記のLBPを、LBP−1、LBP−2及びLBP−3よりなる群から 選択する、請求項90に記載の方法。 92.前記の細胞を、細胞培養又は組織培養から得る、請求項90に記載の方法 。 93.前記の細胞を、胎児繊維芽細胞から得る、請求項90に記載の方法。 94.前記の細胞が、動物の一部である、請求項90に記載の方法。 95.前記の動物が、非ヒトトランスジェニック動物である、請求項94に記載 の方法。 96.動物におけるアテローム性動脈硬化症を治療するための医薬組成物であっ て、下記を含む当該医薬組成物: 治療上有効な量の薬剤(該薬剤は、該アテローム性動脈硬化症の治療を生じるよ うに該動物におけるLBP代謝又は構造の面を変えることができる);及び 製薬上許容し得るキャリアー。 97.前記の薬剤が、LBPポリペプチド若しくは核酸であり、又は生物学的に 活性なその断片若しくはアナログである、請求項96に記載の医薬組成物。 98.前記の薬剤が、約50アミノ酸残基長以下のポリペプチドである、請求項 96に記載の医薬組成物。 99.前記の薬剤が、少なくとも約20%の酸性アミノ酸残基を含むアミノ酸配 列を有するポリペプチドである、請求項96に記載の医薬組成物。 100.下記を含む、動物におけるアテローム性動脈硬化症を治療するためのワ クチン組成物:治療上有効な量の薬剤(該薬剤は、該アテローム性動脈硬化症の 治療を生じるように、該動物におけるLBP代謝又は構造の面を変えることがで きる);及び 製薬上許容し得るキャリアー。 101.動物におけるアテローム性動脈硬化症病変の診断方法であって、下記を 含む当該方法: アテローム性動脈硬化症病変中に存在するLBPに結合することのできる標識 した薬剤を準備し; 該標識した薬剤を該動物に、標識されたLBPが生じるように、該標識した薬 剤が該LBPと相互作用する条件下で投与し;そして 該標識されたLBPの位置決定及び定量を、該動物中のアテローム性動脈硬化 症病変の存在を診断するようにイメージングにより行う。 102.前記のLBPを、LBP−1、LBP−2及びLBP−3よりなる群か ら選択する、請求項101に記載の方法。 103.前記のイメージングを、磁気共鳴イメージング、ガンマーカメライメー ジング、単一光子放出コンピュータートモグラフィー(SPECT)イメージング 及びポジトロン放出トモグラフィー(PET)よりなる群から選択する、請求項1 01に記載の方法。 104.LBP又はその断片若しくはアナログに対して動物を免疫化する方法: LDLを有する動物を準備し; LBP又はその断片若しくはアナログを準備し; 該LBP又はその断片若しくはアナログを該動物に、該動物による該LBP又 はその断片若しくはアナログに対する抗体産生を刺激するように、該LBPの該 LDLへの結合が変化するように投与する。 105.前記のLBPの前記のLDLへの結合が減少する、請求項104に記載 の方法。 106.改変したLDL及びネイティブなLDLに結合する能力を有するLBP ポリペプチドの断片又はアナログの作製方法であって、下記を含む当該方法: LBPポリペプチドを準備し; 該LBPポリペプチドの配列を変化させ;そして 該変化させたLBPポリペプチドを、改変したLDL及びネイティブなLDL に結合する能力について試験する。 107.前記のLBPを、LBP−1、LBP−2及びLBP−3よりなる群か ら選択する、請求項106に記載の方法。 108.前記の変化させたLBPポリペプチドを、アンタゴニスト、アゴニスト 及びスーパーアゴニストよりなる群から選択する、請求項106に記載の方法。 109.下記を含む、LBPをコードするcDNAを単離する方法: cDNAライブラリーを準備し; 該cDNAライブラリーをネイティブなLDL及び改変したLDLに結合する ポリペプチドをコードするcDNAについてスクリーニングし;そして 該ポリペプチドをコードする該LBPをコードするcDNAを単離する。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3193096P | 1996-11-27 | 1996-11-27 | |
US60/031,930 | 1996-11-27 | ||
US4854797P | 1997-06-03 | 1997-06-03 | |
US60/048,547 | 1997-06-03 | ||
PCT/US1997/021857 WO1998023282A1 (en) | 1996-11-27 | 1997-11-26 | Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001506983A true JP2001506983A (ja) | 2001-05-29 |
JP2001506983A5 JP2001506983A5 (ja) | 2005-08-11 |
JP4184437B2 JP4184437B2 (ja) | 2008-11-19 |
Family
ID=26707786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52487098A Expired - Fee Related JP4184437B2 (ja) | 1996-11-27 | 1997-11-26 | 新規な低密度リポ蛋白質結合性蛋白質並びにアテローム性動脈硬化症の診断及び治療におけるそれらの利用 |
Country Status (10)
Country | Link |
---|---|
US (2) | US6355451B1 (ja) |
EP (1) | EP0969855B1 (ja) |
JP (1) | JP4184437B2 (ja) |
AT (1) | ATE317264T1 (ja) |
AU (1) | AU736142B2 (ja) |
CA (1) | CA2272243A1 (ja) |
DE (1) | DE69735243T2 (ja) |
ES (1) | ES2258798T3 (ja) |
IL (1) | IL129910A0 (ja) |
WO (1) | WO1998023282A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009154025A1 (ja) | 2008-06-20 | 2009-12-23 | 国立大学法人岡山大学 | 酸化LDL/β2GPI複合体に対する抗体及びその用途 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605588B1 (en) | 1996-11-27 | 2003-08-12 | Boston Heart Foundation, Inc. | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
US6632923B1 (en) | 1996-11-27 | 2003-10-14 | Boston Heart Foundation, Inc. | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
WO2002102250A1 (en) * | 1999-10-22 | 2002-12-27 | Glaxo Group Limited | $g(in vivo) imaging |
CN1329142A (zh) * | 2000-06-21 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——rna聚合酶ii相关蛋白11.33和编码这种多肽的多核苷酸 |
US20060032508A1 (en) * | 2000-12-20 | 2006-02-16 | Fox Hollow Technologies, Inc. | Method of evaluating a treatment for vascular disease |
US20050154407A1 (en) * | 2000-12-20 | 2005-07-14 | Fox Hollow Technologies, Inc. | Method of evaluating drug efficacy for treating atherosclerosis |
US7794413B2 (en) * | 2005-04-19 | 2010-09-14 | Ev3, Inc. | Libraries and data structures of materials removed by debulking catheters |
CN104519898A (zh) * | 2012-06-06 | 2015-04-15 | 国家健康与医学研究院 | 用于治疗癌症的方法和药物组合物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59206046A (ja) * | 1983-05-11 | 1984-11-21 | Asahi Chem Ind Co Ltd | 低比重リポ蛋白質を吸着する材料 |
US4660563A (en) | 1984-12-31 | 1987-04-28 | Massachusetts Institute Of Technology | Method and means for detection of arterial lesions |
US4877599A (en) | 1986-11-10 | 1989-10-31 | New England Deaconess Hospital Corporation | Detection of vascular disease with labelled antibodies |
US5726153A (en) | 1988-05-02 | 1998-03-10 | New England Deaconess Hospital Corporation | Synthetic peptides for arterial imaging |
US5135848A (en) | 1989-10-23 | 1992-08-04 | Lehigh University And Northeast Benjamin Franklin Technology Center Of Pa | Methods for evaluating cholesterol metabolism and reagents therefor |
US5196324A (en) * | 1989-12-15 | 1993-03-23 | Eli Lilly And Company | Monoclonal antibodies reactive with a human atheroma associated antigen |
JPH05507276A (ja) * | 1990-05-03 | 1993-10-21 | ニュー・イングランド・ディーコネス・ホスピタル・コーポレイション | 動脈造影用合成ペプチド類 |
DE4222385A1 (de) | 1992-07-08 | 1994-01-13 | Boehringer Ingelheim Int | Verfahren zur Isolierung von Inhibitoren des Rhinovirus-Rezeptors |
EP0586094A1 (en) | 1992-08-03 | 1994-03-09 | Wisconsin Alumni Research Foundation | Soluble LDL receptor and gene |
AU6234194A (en) | 1993-01-15 | 1994-08-15 | Board Of Regents, The University Of Texas System | High molecular weight b-cell growth factor: interleukin-14 |
JPH09163988A (ja) | 1995-10-09 | 1997-06-24 | Kowa Co | 新規なldl受容体類似蛋白質及び遺伝子 |
-
1997
- 1997-11-26 ES ES97949680T patent/ES2258798T3/es not_active Expired - Lifetime
- 1997-11-26 AU AU74088/98A patent/AU736142B2/en not_active Ceased
- 1997-11-26 US US08/979,608 patent/US6355451B1/en not_active Expired - Fee Related
- 1997-11-26 CA CA002272243A patent/CA2272243A1/en not_active Abandoned
- 1997-11-26 AT AT97949680T patent/ATE317264T1/de not_active IP Right Cessation
- 1997-11-26 JP JP52487098A patent/JP4184437B2/ja not_active Expired - Fee Related
- 1997-11-26 DE DE69735243T patent/DE69735243T2/de not_active Expired - Lifetime
- 1997-11-26 EP EP97949680A patent/EP0969855B1/en not_active Expired - Lifetime
- 1997-11-26 IL IL12991097A patent/IL129910A0/xx unknown
- 1997-11-26 WO PCT/US1997/021857 patent/WO1998023282A1/en active IP Right Grant
-
2001
- 2001-09-24 US US09/962,055 patent/US20020052033A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009154025A1 (ja) | 2008-06-20 | 2009-12-23 | 国立大学法人岡山大学 | 酸化LDL/β2GPI複合体に対する抗体及びその用途 |
US8575314B2 (en) | 2008-06-20 | 2013-11-05 | National University Corporation Okayama University | Antibody against oxidized LDL/β2GPI complex and use of the same |
Also Published As
Publication number | Publication date |
---|---|
ATE317264T1 (de) | 2006-02-15 |
DE69735243T2 (de) | 2006-11-02 |
DE69735243D1 (de) | 2006-04-20 |
US20020052033A1 (en) | 2002-05-02 |
EP0969855B1 (en) | 2006-02-08 |
JP4184437B2 (ja) | 2008-11-19 |
AU7408898A (en) | 1998-06-22 |
US6355451B1 (en) | 2002-03-12 |
AU736142B2 (en) | 2001-07-26 |
EP0969855A1 (en) | 2000-01-12 |
IL129910A0 (en) | 2000-02-29 |
EP0969855A4 (en) | 2001-08-16 |
WO1998023282A1 (en) | 1998-06-04 |
CA2272243A1 (en) | 1998-06-04 |
ES2258798T3 (es) | 2006-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7807384B2 (en) | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis | |
US6605588B1 (en) | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis | |
US7060270B2 (en) | Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins | |
US7273751B2 (en) | Vascular endothelial growth factor-2 | |
JP2002505873A (ja) | 血管内皮増殖因子2 | |
JPH10504804A (ja) | リポ多糖の中和用組成物 | |
JP2001506983A (ja) | 新規な低密度リポ蛋白質結合性蛋白質並びにアテローム性動脈硬化症の診断及び治療におけるそれらの利用 | |
JP2002530062A (ja) | 12個のヒト分泌タンパク質 | |
JP2000515507A (ja) | 平滑筋細胞が関連する疾患を処置するためのt―bam(cd40l)技術の治療適用 | |
US6849413B2 (en) | PGRP-L polynucleotides, polypeptides, and antibodies | |
JP2003528580A (ja) | ヒトニューロペプチドレセプター | |
JP2000512506A (ja) | 新規化合物 | |
AU769970B2 (en) | Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis | |
JP2002527104A (ja) | Tnfr関連遺伝子12 | |
JP6236665B2 (ja) | 癌転移マーカー及びそれを用いた癌転移の診断方法 | |
WO2000008050A1 (en) | Dna encoding human monocyte-macrophage apolipoprotein b receptor gene and protein | |
US20100055114A1 (en) | Use of integrin alpha 10 binding antibody to modulate extracellular matrix (cartilage) turnover | |
US20030082532A1 (en) | Tumor necrosis factor receptor related gene 12 polypeptides | |
AU2002359350A1 (en) | Monoclonal antibodies specific for beta-amyloid. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041125 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070410 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070710 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071010 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080812 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080904 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110912 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110912 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120912 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |